{
    "2018-08-14": [
        [
            {
                "time": "2018-08-14",
                "original_text": "重磅！恒瑞「吡咯替尼」获批上市",
                "features": {
                    "keywords": [
                        "恒瑞",
                        "吡咯替尼",
                        "获批上市"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-08-14",
                "original_text": "8月14日复盘：缩量后的演变 主力重点出击10股(名单)",
                "features": {
                    "keywords": [
                        "复盘",
                        "缩量",
                        "主力重点出击"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-08-06",
                "original_text": "【山证医药】医药生物行业周报（20180806-20180812）：挖掘估值切换带来的优质股价值投资机会",
                "features": {
                    "keywords": [
                        "医药生物",
                        "估值切换",
                        "优质股",
                        "价值投资"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-14",
                "original_text": "医药生物：境外急需新药上市加速 优先审评工作稳步推进",
                "features": {
                    "keywords": [
                        "医药生物",
                        "境外急需新药",
                        "上市加速",
                        "优先审评"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-08-14",
                "original_text": "恒瑞医药上半年营收增长两成",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "营收增长",
                        "两成"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-14",
                "original_text": "国盛证券：净流入再超百亿 消费股重获增配",
                "features": {
                    "keywords": [
                        "国盛证券",
                        "净流入",
                        "消费股",
                        "增配"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "消费"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-14",
                "original_text": "295亿资金争夺20股：主力资金重点出击3股(名单)",
                "features": {
                    "keywords": [
                        "资金争夺",
                        "主力资金",
                        "重点出击"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-14",
                "original_text": "医药生物行业周报:信心恢复,把握价值机会",
                "features": {
                    "keywords": [
                        "医药生物",
                        "信心恢复",
                        "价值机会"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-14",
                "original_text": "医药生物行业周报:板块性性价比回升,持续推荐绩优龙头",
                "features": {
                    "keywords": [
                        "医药生物",
                        "板块性性价比",
                        "绩优龙头"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-14",
                "original_text": "恒瑞医药:业绩符合预期创新+国际化稳步推进",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "业绩符合预期",
                        "创新",
                        "国际化"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}